NEW YORK (GenomeWeb) – Synthetic biology firm Gen9 has raised $25 million in a private financing round, its president and CEO confirmed to GenomeWeb Daily News.

The company disclosed the financing in a document filed with the US Securities and Exchange Commission last week. Gen9 President and CEO Kevin Munelly told GWDN in an email today that proceeds from the financing will be used to "expand our team and advance additional products and services that will further accelerate the design-build-test cycle for our customers."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."